Annual SG&A
$11.99 M
-$13.68 M-53.28%
31 December 2023
Summary:
AcelRx Pharmaceuticals annual selling, general & administrative expenses is currently $11.99 million, with the most recent change of -$13.68 million (-53.28%) on 31 December 2023. During the last 3 years, it has fallen by -$18.94 million (-61.23%).ACRX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.79 M
+$547.00 K+24.33%
31 December 2023
Summary:
AcelRx Pharmaceuticals quarterly selling, general & administrative expenses is currently $2.79 million, with the most recent change of +$547.00 thousand (+24.33%) on 31 December 2023.ACRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.76 B
-$18.40 M-1.06%
31 December 2023
Summary:
AcelRx Pharmaceuticals TTM selling, general & administrative expenses is currently -$1.76 billion, with the most recent change of -$18.40 million (-1.06%) on 31 December 2023.ACRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -61.2% | -53.1% | -5777.3% |
| 5 y5 years | -73.4% | -78.1% | -4000.5% |
ACRX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -73.4% | -79.0% | -3731.5% |
AcelRx Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $11.99 M(-53.3%) | $2.79 M(+24.3%) | $11.99 M(-22.4%) |
| Sept 2023 | - | $2.25 M(-15.8%) | $15.45 M(-16.3%) |
| June 2023 | - | $2.67 M(-37.6%) | $18.46 M(-6.5%) |
| Mar 2023 | - | $4.28 M(-31.5%) | $19.75 M(+0.9%) |
| Dec 2022 | $25.67 M(-17.0%) | $6.25 M(+18.8%) | $19.57 M(+1.5%) |
| Sept 2022 | - | $5.26 M(+32.9%) | $19.28 M(-14.9%) |
| June 2022 | - | $3.96 M(-3.4%) | $22.66 M(-17.3%) |
| Mar 2022 | - | $4.10 M(-31.2%) | $27.39 M(-11.5%) |
| Dec 2021 | $30.93 M(-14.8%) | $5.96 M(-31.1%) | $30.93 M(-5.8%) |
| Sept 2021 | - | $8.64 M(-0.6%) | $32.82 M(+3.3%) |
| June 2021 | - | $8.69 M(+13.7%) | $31.78 M(+3.6%) |
| Mar 2021 | - | $7.64 M(-2.6%) | $30.66 M(-15.6%) |
| Dec 2020 | $36.33 M(-19.3%) | $7.85 M(+3.3%) | $36.33 M(-12.0%) |
| Sept 2020 | - | $7.60 M(+0.3%) | $41.27 M(-7.5%) |
| June 2020 | - | $7.58 M(-43.1%) | $44.61 M(-7.8%) |
| Mar 2020 | - | $13.31 M(+4.1%) | $48.36 M(+7.4%) |
| Dec 2019 | $45.03 M(+116.8%) | $12.79 M(+16.9%) | $45.03 M(+12.9%) |
| Sept 2019 | - | $10.94 M(-3.5%) | $39.89 M(+16.8%) |
| June 2019 | - | $11.33 M(+13.6%) | $34.14 M(+27.6%) |
| Mar 2019 | - | $9.98 M(+30.4%) | $26.76 M(+28.9%) |
| Dec 2018 | $20.77 M(+25.0%) | $7.65 M(+47.4%) | $20.77 M(+22.0%) |
| Sept 2018 | - | $5.19 M(+31.5%) | $17.03 M(+4.8%) |
| June 2018 | - | $3.94 M(-1.0%) | $16.24 M(-1.3%) |
| Mar 2018 | - | $3.98 M(+1.9%) | $16.46 M(-0.9%) |
| Dec 2017 | $16.61 M(+6.5%) | $3.91 M(-11.3%) | $16.61 M(-1.0%) |
| Sept 2017 | - | $4.41 M(+6.0%) | $16.78 M(+1.6%) |
| June 2017 | - | $4.16 M(+0.4%) | $16.52 M(+3.5%) |
| Mar 2017 | - | $4.14 M(+1.5%) | $15.96 M(+2.3%) |
| Dec 2016 | $15.60 M | $4.08 M(-1.6%) | $15.60 M(+0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | $4.14 M(+15.2%) | $15.54 M(+8.5%) |
| June 2016 | - | $3.60 M(-4.8%) | $14.32 M(+6.4%) |
| Mar 2016 | - | $3.78 M(-6.0%) | $13.46 M(-5.2%) |
| Dec 2015 | $14.20 M(-22.6%) | $4.02 M(+37.1%) | $14.20 M(-4.7%) |
| Sept 2015 | - | $2.93 M(+7.1%) | $14.91 M(-10.3%) |
| June 2015 | - | $2.73 M(-39.5%) | $16.63 M(-12.2%) |
| Mar 2015 | - | $4.52 M(-4.3%) | $18.94 M(+3.2%) |
| Dec 2014 | $18.35 M(+85.7%) | $4.72 M(+1.6%) | $18.35 M(+8.4%) |
| Sept 2014 | - | $4.65 M(-7.9%) | $16.93 M(+16.0%) |
| June 2014 | - | $5.05 M(+28.6%) | $14.59 M(+25.6%) |
| Mar 2014 | - | $3.92 M(+18.7%) | $11.61 M(+17.6%) |
| Dec 2013 | $9.88 M(+37.2%) | $3.31 M(+43.1%) | $9.88 M(+16.5%) |
| Sept 2013 | - | $2.31 M(+11.6%) | $8.48 M(+11.9%) |
| June 2013 | - | $2.07 M(-5.5%) | $7.58 M(+4.0%) |
| Mar 2013 | - | $2.19 M(+14.8%) | $7.29 M(+1.2%) |
| Dec 2012 | $7.20 M(+5.9%) | $1.91 M(+35.4%) | $7.20 M(+2.8%) |
| Sept 2012 | - | $1.41 M(-20.6%) | $7.00 M(-6.1%) |
| June 2012 | - | $1.78 M(-15.6%) | $7.46 M(+2.0%) |
| Mar 2012 | - | $2.10 M(+22.8%) | $7.31 M(+7.6%) |
| Dec 2011 | $6.80 M(+70.3%) | $1.71 M(-8.1%) | $6.80 M(+12.5%) |
| Sept 2011 | - | $1.87 M(+14.5%) | $6.04 M(+14.7%) |
| June 2011 | - | $1.63 M(+2.6%) | $5.27 M(+7.2%) |
| Mar 2011 | - | $1.59 M(+65.5%) | $4.92 M(+22.9%) |
| Dec 2010 | $3.99 M(+13.1%) | $960.00 K(-11.9%) | $4.00 M(-1.5%) |
| Sept 2010 | - | $1.09 M(-14.6%) | $4.06 M(+36.7%) |
| June 2010 | - | $1.28 M(+89.9%) | $2.97 M(+75.5%) |
| Mar 2010 | - | $672.00 K(-34.1%) | $1.69 M(+65.9%) |
| Dec 2009 | $3.53 M(+49.2%) | $1.02 M | $1.02 M |
| Dec 2008 | $2.37 M | - | - |
FAQ
- What is AcelRx Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for AcelRx Pharmaceuticals?
What is AcelRx Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of ACRX is $11.99 M
What is the all time high annual SG&A for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high annual selling, general & administrative expenses is $45.03 M
What is AcelRx Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of ACRX is $2.79 M
What is the all time high quarterly SG&A for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $13.31 M
What is AcelRx Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of ACRX is -$1.76 B
What is the all time high TTM SG&A for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high TTM selling, general & administrative expenses is $48.36 M